Background: TRISS methodology estimates probability of survival (P(s)) based on coefficients derived largely from adult data. We developed a novel pediatric age-specific method to estimate P(s).
Methods: The Pennsylvania Trauma Outcome Study database was queried for pediatric patients injured between 1993 and 1996 (n = 9730). P(s) derived from the Pediatric Age-Adjusted TRISS (PAAT) methodology was generated using our Age-Specific Pediatric Trauma Score and Injury Severity Score with corresponding weights. A test data set of 7138 pediatric patients entered in the Pennsylvania Trauma Outcome Study from 1997 to 1999 was used to compute an expected number of survivors for PAAT, TRISS, and ASCOT (A Severity Characteristic of Trauma). Observed and expected survival were compared for blunt injured patients, for head injured patients, and by age category.
Results: PAAT showed no significant difference between observed and expected survival. TRISS and ASCOT significantly underestimated overall survival: across age groups, for blunt injuries, for head injuries, and for patients whose P(s) was less than 91%.
Conclusion: PAAT offers a more reliable methodology than TRISS and ASCOT for comparing pediatric trauma outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00005373-200202000-00006 | DOI Listing |
JAMA Pediatr
January 2025
Department of Cardiology, Harvard Medical School and Boston Children's Hospital, Boston, Massachusetts.
Importance: Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening complication of COVID-19 infection. Data on midterm outcomes are limited.
Objective: To characterize the frequency and time course of cardiac dysfunction (left ventricular ejection fraction [LVEF] <55%), coronary artery aneurysms (z score ≥2.
JAMA Neurol
January 2025
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.
Neurology
January 2025
The Dubowitz Neuromuscular Centre, Developmental Neurosciences Department, University College London, Great Ormond Street Institute of Child Health, United Kingdom.
Background And Objectives: Safety and efficacy of IV onasemnogene abeparvovec has been demonstrated for patients with spinal muscular atrophy (SMA) weighing <8.5 kg. SMART was the first clinical trial to evaluate onasemnogene abeparvovec for participants weighing 8.
View Article and Find Full Text PDFJ Asthma
January 2025
Division of Pediatric Allergy and Immunology, Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Objective: It is well known that children who suffer from obesity and asthma may also have exercise-induced bronchospasm. Exhaled nitric oxide is an indicator of airway inflammation, and could be affected by exercise. This study looked at how exercise, which is a typical cause of acute airway obstruction, affects the levels of FeNO and in obese and asthmatic children.
View Article and Find Full Text PDFSpine Deform
January 2025
Scottish Rite for Children, 2222 Welborn Street, Dallas, TX, 75219, USA.
Purpose: To compare health-related quality-of-life (HRQOL) between children with hyperkyphosis and idiopathic scoliosis using 9-item Oswestry Disability Index (ODI-9) and Patient Reported Outcome Measurement Information System (PROMIS) Pain Interference, Mobility, and Anxiety.
Methods: Children with hyperkyphosis, idiopathic scoliosis, and controls with no structural diagnosis ages 10-18 years who completed the PROMIS Pediatric Pain Interference, Mobility, and Anxiety domains were retrospectively evaluated from April 2021 to June 2023. Comparisons were made between hyperkyphosis, idiopathic scoliosis, and control groups.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!